---
title: "Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286890035.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-05-19T09:16:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286890035.md)
  - [en](https://longbridge.com/en/news/286890035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286890035.md)
---

# Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [ECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight loss](https://longbridge.com/en/news/286442888.md)
- [ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition](https://longbridge.com/en/news/286276857.md)
- [Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas](https://longbridge.com/en/news/286759146.md)
- [ECO 2026: tirzepatide shows potential for T1D treatment](https://longbridge.com/en/news/286575591.md)